Renal cell carcinoma Trials in Cleveland, United States
Conditions / Renal cell carcinoma / Cleveland, United States
Clinical trials for Renal cell carcinoma investigate a range of treatment strategies and patient populations.
37 total trials for this combination
Showing top 10 of 37 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | COMPLETED | PHASE3 |
| NCT00898365 | Study of Kidney Tumors in Younger Patients | ACTIVE_NOT_RECRUITING | — |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | TERMINATED | PHASE1/PHASE2 |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | COMPLETED | PHASE1 |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | TERMINATED | PHASE1 |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | ACTIVE_NOT_RECRUITING | PHASE2 |